Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.42 USD | +3.95% | +3.24% | -10.73% |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.73% | 466M | |
+8.29% | 115B | |
+13.01% | 107B | |
-13.57% | 22.31B | |
-3.99% | 21.6B | |
-5.79% | 18.23B | |
-39.93% | 17.62B | |
+7.34% | 14.26B | |
+33.48% | 12.37B | |
-28.24% | 8.28B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd. Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-09-2021 08